AGIO Chief Medical Officer Sarah Gheuens Buys 3,000 Shares

Chief Medical Officer Expands Stake

Sarah Gheuens, the chief medical officer of Agios Pharmaceuticals, Inc. (NasdaqGS: AGIO), picked up 3,000 shares of the biotechnology company on June 18, 2026. The purchase added to her holdings in the Cambridge, Massachusetts-based firm as part of an active period of corporate leadership buying.

Broad Insider Purchasing Wave

The transaction did not happen in isolation, as several other leaders at the biotechnology firm stepped up to buy shares on June 18, 2026. Rahul Ballal, Jay Backstrom, David Scadden, and Jacqualyn Fouse each acquired 14,950 shares on the same date. Cynthia Smith also grew her stake by purchasing 2,816 shares, rounding out a synchronized round of open-market acquisitions across the executive team and board.

Stock Trades Near Moving Averages

Shares of Agios Pharmaceuticals change hands around $35.47, sitting close to its 50-day moving average of $34.43 and comfortably past its 200-day moving average of $30.75. The equity has moved within a 52-week range spanning from a low of $22.24 to a high of $46.00. That positioning puts the stock roughly in the middle of its yearly bounds as the market tracks upcoming catalysts.

Recent Financial Results

The biotechnology firm posted $98.34 million in revenue with a revenue growth rate of 2.59%. Its bottom-line figures show an EPS of -7.01 alongside a return on equity of -34.34%. Investors look toward the company's next scheduled financial update on October 29, 2026, to check on progress for treatments targeting rare blood disorders and cellular metabolism.

Analysts Set New Price Targets

Wall Street firms have kept a steady eye on the biotechnology company through the summer and autumn. On July 7, 2026, RBC Capital maintained a sector perform rating with a target of $32.00. HC Wainwright & Co. adjusted its target to $52.00 from $54.00 on July 21, 2026, before keeping a buy rating with a $55.00 target on July 30, 2026. Citigroup maintained a buy rating on July 31, 2026, moving its target to $52.00 from $46.00, while Truist Securities updated its view on the same day with a $39.00 target. Into August, JP Morgan maintained a neutral rating with a $34.00 target on August 7, 2026. Later in the cycle, B of A Securities kept a buy rating and lifted its target to $50.00 from $46.00 on September 21, 2026. Most recently, Truist Securities kept a buy rating while shifting its target to $37.00 from $39.00 on October 7, 2026.

Focus on Cellular Metabolism

Agios Pharmaceuticals discovers and develops treatments focused on cellular metabolism. Its lead product, PYRUKYND, is an activator used for treating hemolytic anemias and sickle cell disease, alongside other pipeline candidates addressing thalassemia and rare genetic conditions. Executive transactions reported on Form 4 filings provide a look at how leaders manage their personal capital in the business, though they do not guarantee future stock directions.